Bayer Aktiengesellschaft (OTCMKTS:BAYRY) Issues FY 2024 Earnings Guidance

Bayer Aktiengesellschaft (OTCMKTS:BAYRY) issued an update on its FY 2024 earnings guidance on Tuesday morning. The company provided earnings per share guidance of 5.610-6.045 for the period. The company issued revenue guidance of $51.7 billion-$53.9 billion.

Analysts Set New Price Targets

Separately, Bank of America upgraded Bayer Aktiengesellschaft from an “underperform” rating to a “neutral” rating in a research note on Friday, September 6th. One analyst has rated the stock with a sell rating and eight have assigned a hold rating to the company’s stock. According to data from MarketBeat.com, Bayer Aktiengesellschaft currently has a consensus rating of “Hold”.

Bayer Aktiengesellschaft Trading Down 0.3 %

Bayer Aktiengesellschaft stock opened at $6.45 on Tuesday. Bayer Aktiengesellschaft has a 12-month low of $6.39 and a 12-month high of $11.33. The company has a quick ratio of 0.86, a current ratio of 1.27 and a debt-to-equity ratio of 1.04. The firm’s fifty day moving average price is $7.48 and its 200 day moving average price is $7.45.

Bayer Aktiengesellschaft Company Profile

Bayer Aktiengesellschaft, together its subsidiaries, operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, and Crop Science segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women’s health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and digital solutions, and contrast agents, as well as cell and gene therapy.